Berenberg Bank Boosts Moderna (NASDAQ:MRNA) Price Target to $42.00

Moderna (NASDAQ:MRNA) had its target price upped by Berenberg Bank from $33.00 to $42.00 in a report published on Thursday. They currently have a hold rating on the stock.

MRNA has been the subject of a number of other reports. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research note on Monday, November 18th. Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. reduced their price target on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a research note on Tuesday, November 26th. Finally, Barclays cut their target price on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Four investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $75.58.

Moderna Stock Performance

Moderna stock opened at $34.06 on Thursday. Moderna has a 12-month low of $31.94 and a 12-month high of $170.47. The company has a market capitalization of $13.11 billion, a price-to-earnings ratio of -5.85 and a beta of 1.60. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The firm’s fifty day moving average price is $40.85 and its 200 day moving average price is $66.40.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the previous year, the firm earned ($1.39) EPS. The company’s revenue was up 3.8% on a year-over-year basis. On average, research analysts forecast that Moderna will post -9.3 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 2,664 shares of company stock valued at $115,210 over the last ninety days. 15.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MRNA. State Street Corp raised its stake in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after buying an additional 906,114 shares during the period. Two Sigma Advisers LP acquired a new position in shares of Moderna in the third quarter valued at approximately $23,825,000. International Assets Investment Management LLC increased its stake in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after buying an additional 316,552 shares during the period. Finally, Douglas Lane & Associates LLC increased its position in Moderna by 62.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after purchasing an additional 298,715 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.